| 摘要 |
A monoclonal antibody (MA6) directed against interleukin-6 receptor ( IL-6R) recognises an epitope which is the same as that recognised by one of the IgG1 monoclonal antibodies B-F19, B-R6 or B-N12 produced by hybridomas CNCM I-1256, 1255 and 1257 respectively. Also claimed are the hybridomas I-1256, 1255 and 1257, and a diagnostic reagent contg. the above Ab. Pref., these contain 0.5-5 (esp. 1) mg MAb/ml, MAb are pref. formulated with other MAbs to produce polymeric complexes between soluble IL-6R and the antibodies. Such complexes are eliminated move quickly than those formed from a single antibody. USE - MAb inhibit or suppress growth of IL-6 dependent cells so can be used to treat or prevent IL-6 associated diseases, specifically multiple myeloma; myeloid leukaemia; Castleman disease; systemic lupus erythematosus; kidney cancer and inflammatory arthropathy MAb can be coupled to a toxin, radioactive cpd. or other therapeutic agent. The MAb can also be used to detect or quantify (e.g. by ELISA) IL-6R, including its soluble forms and epitopes.
|
